HUMAN MESENCHYMAL STEM CELL-DERIVED CONDITIONED MEDIA (MSC-CM) PROTECTS HUMAN MICROVASCULAR ENDOTHELIAL CELLS FROM SHIGA TOXIN TYPE 2 CYTOTOXICITY.

VELEZ GUTIERREZ DANIEL; FIORE ESTEBAN; GOMEZ FERNANDO; GARCIA MARIANA; IBARRA CRISTINA; AMARAL MARÍA M

Mar del Plata

Congreso; Reunión Anual SAIC SAFE SAB SAP 2019; 2019

SAIC SAFE SAB SAP

Hemolytic uremic syndrome (HUS) is theclinical triad of thrombocytopenia, anemia, and acute renalfailure (ARF). HUS is classically associated with Shiga toxin?producing Escherichia coli infection and affects mainly childrenunder 5 years old. Argentina exhibits the highest incidence ratein the world. HUS lacks a specific treatment and many patientsdevelop chronic kidney disease. Recently, mesenchymalstem/stromal cells (MSCs) have been proposed to treat the ARF.MSCs release several antiapoptotic and proliferative mediatorsthat could mitigate the cytotoxic effects caused by Stx2 on renalcells. The objectives of this work were to isolate human MSCsand to analyze if whether the human mesenchymal stem cellderived conditioned media (MSC-CM) would be able to protecthuman glomerular endothelial cells (HGEC) from the detrimentaleffects of Stx2. MSCs were isolated by culturing explants ofWarthon?s Jelly from human umbilical cord. Then, cells weresubcultured and MSC-CM was collected after 24 h of incubation.HGEC were treated with Stx2 (0.5 ng/ml) and in the presence ornot of MSC-CM. After 72 h, cell viability was analyzed by neutralred uptake. Cell morphology analysis was evaluated by lightmicroscopy after staining with H&E. Cell counts were performedon four fields and cell area values were obtained using Image Jsoftware. Results are expressed as percentage respect tocontrols (100 %). MSC-CM significantly protected in about 30 %the HGEC viability (p